Skip to main content
SpringerLink
Log in

Neuro-Oncologic Complications of Breast Cancer

  • Chapter
Cancer Neurology in Clinical Practice

  • 167 Accesses

Abstract

Breast cancer arises from the epithelial cells that line the ducts and lobules of the mammary gland. Its incidence has increased gradually (1–2%/yr for the last three decades), but recently the incidence has leveled off and mortality has even decreased slightly. At present, about 1 out of every 10 females in the United States and Western Europe will develop breast cancer. The risk of breast cancer rises steadily from about the age of 25, with some slowing of increase after menopause. Obviously, hormones are important promoters of the disease. Length of menstrual life and the fraction until first pregnancy are established risk factors of breast cancer. Other factors include exposure to radiotherapy (RT) before the age of 30, and to some extent long-term postmenopausal estrogen replacement. A family history of breast cancer is the most important risk factor (1). About 5-10% of all breast cancers occur in high-risk families, including families with the Li-Fraumeni syndrome (mutation in p53) and families with mutation in the tumor suppressor gene BRCA 1 or BRCA 2 (lifetime risk of breast cancer up to 85%). In sporadic breast cancer p53 mutation is found in 40% of the patients and overexpression of the oncogene erb B2 (HER-2/neu) in a quarter of the patients (2).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer. N Engl J Med 2000; 342: 564–571.

    Article  PubMed  CAS  Google Scholar 

  2. Hanna W, Kahn HJ, Trudeau M. Evaluation of HER-2/neu (erbB2) status in breast cancer: from bench to bedside. Mod Pathol 1999; 12: 827–834.

    PubMed  CAS  Google Scholar 

  3. Lee Y-TN. Patterns of metastasis and natural courses of breast carcinoma. Cancer Metast Rev 1985; 4: 153–172.

    Article  CAS  Google Scholar 

  4. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography: a meta-analysis. JAMA 1995; 273: 149–154.

    Article  PubMed  CAS  Google Scholar 

  5. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339: 974–984.

    Article  PubMed  CAS  Google Scholar 

  6. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. ErbB-2 and response to doxorubicin inpatients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90: 1361–1370.

    Article  PubMed  CAS  Google Scholar 

  7. Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CC, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 1998; 352: 515–521.

    Article  PubMed  CAS  Google Scholar 

  8. Stadtmauer EA, O’Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 2000; 342: 1069–1076.

    Article  PubMed  CAS  Google Scholar 

  9. Viadana E, Bross ID, Pickren JW. An autopsy study of some routes of dissemination of cancer of the breast. Br J Cancer 1973; 27: 336–340.

    Article  PubMed  CAS  Google Scholar 

  10. Hagemeister FB, Buzdar AU, Lunda MA, Blumenschein GR. Causes of death in breast cancer: a clinicopathologic study. Cancer 1980; 46: 162–167.

    Article  PubMed  Google Scholar 

  11. Tsukada Y, Fouad A, Pickren J, Lane W. Central nervous system metastasis from breast carcinoma: autopsy study. Cancer 1983; 52: 2349–2354.

    Article  PubMed  CAS  Google Scholar 

  12. Kamby C. The pattern of metastases in human breast cancer: methodological aspects and influence of prognostic factors. Cancer Treatm Rev 1990; 17: 37–61.

    Article  CAS  Google Scholar 

  13. Distefano A, Yap Y, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer 1979: 44: 1913–1918.

    Article  PubMed  CAS  Google Scholar 

  14. Boogerd W, Vos VW, Hart AA, Baris G. Brain metastases in breast cancer; natural history, prognostic factors and outcome. J NeuroOncol 1993; 15: 165–174.

    Article  PubMed  CAS  Google Scholar 

  15. Posner JB. Neurologic Complications of Cancer. F.A. Davis, Philadelphia, 1995.

    Google Scholar 

  16. Kamby C, Soerensen PS. Characteristics of patients with short and long survivals after detection of intracranial metastases from breast cancer. J Neuro-Oncol 1988; 6: 37–45.

    Article  CAS  Google Scholar 

  17. Diener-West M, Dobbins TW, Phillips TL, Nelson DF. Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using RTOG study 7916. Int J Radiat Oncol Biol Phys 1989; 16: 669–673.

    Article  PubMed  CAS  Google Scholar 

  18. Borgelt N, Gelber R, Kramer S, Brady L, Chang C, Davis L, et al. The palliation of brain metastases• final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980; 6: 1–19.

    Article  PubMed  CAS  Google Scholar 

  19. Vecht CHJ, Hovestadt A, Verbiest HBC, van Vliet JJ, van Putten WLJ. Dose-effect relation of dexamethasone on brain tumor edema: a randomized study with 16 mg, 8 mg and 4 mg per day. Neurology 1994; 44: 675–680.

    Article  PubMed  CAS  Google Scholar 

  20. Coia LR. The role of radiation therapy in the treatment of brain metastases. Int J Radiat Oncol Biol Phys 1992; 23: 229–238.

    Article  PubMed  CAS  Google Scholar 

  21. Priestman TJ, Dunn J, Brada M, Rampling R, Baker PG. Final results of the Royal College of Radiologists’ trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol 1996; 8: 308–315.

    Article  CAS  Google Scholar 

  22. Auchter RM, Lamond JP, Alexander E, Buatti JM, Chappell R, Friedman WA, et al. A multi-institutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. Int J Radiat Oncol Biol Phys 1996; 35: 27–35.

    Article  PubMed  CAS  Google Scholar 

  23. Muacevic A, Kreth FW, Horstmann GA, Schmid-Elsaesser R, Wowra B, Steiger Hi, et al. Surgery and radiotherapy compared with gamma knife radiosurgery in the treatment of solitary cerebral metastases of small diameter. J Neurosurg 1999; 91: 35–43.

    Article  PubMed  CAS  Google Scholar 

  24. Huang C-F, Kondziolka D, Flickinger JC, Lunsford LD. Stereo-tactic radiosurgery for brainstem metastases. J Neurosurg 1999; 91: 563–568.

    Article  PubMed  CAS  Google Scholar 

  25. Patchell RA, Tibbs PA, Regine WF, Dempsey RI, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain. A randomized trial. JAMA 1998; 280: 1485–1489.

    Article  PubMed  CAS  Google Scholar 

  26. Wronski M, Arbit E, McCormick B. Surgical treatment of 70 patients with brain metastases from breast carcinoma. Cancer 1997; 80: 1746–1754.

    Article  PubMed  CAS  Google Scholar 

  27. Boogerd W, Hart AAM, Tjahja IS. Treatment and outcome of brain metastasis as first site of distant metastasis from breast cancer. J Neuro-Oncol 1997; 35: 161–167.

    Article  CAS  Google Scholar 

  28. Bindal RK, Sawaya R, Leavens ME, Lee JH. Surgical treatment of multiple brain metastases. J. Neurosurg 1993; 79: 210–116.

    Article  PubMed  CAS  Google Scholar 

  29. Rosner D, Takuma N, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986; 58: 832–839.

    Article  PubMed  CAS  Google Scholar 

  30. Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992; 69: 972–980.

    Article  PubMed  CAS  Google Scholar 

  31. Franciosi V, Cocconi G, Michiara M, Costanzo FD, Fosser V, Tonato M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non-small cell lung carcinoma, or malignant melanoma. Cancer 1999; 85: 1599–1605.

    Article  PubMed  CAS  Google Scholar 

  32. Carey RW, Davis JM, Zervas NT. Tamoxifen-induced regression of cerebral metastases in breast carcinoma. Cancer Treatm Rep 1981; 65: 793–795.

    CAS  Google Scholar 

  33. Van der Gaast A, Alexieva-Figusch J, Vecht C, Verweij J, Stoter G. Complete remission of a brain metastases to third-line hormonal treatment with megestrol acetate. Am J Clin Oncol 1990; 13: 507–509.

    Article  PubMed  Google Scholar 

  34. Kaba SE, Kyritsis P, Hess K, Yung WK, Mercier R, Dakhil S, et al. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol 1997; 15: 1063–1070.

    PubMed  CAS  Google Scholar 

  35. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma. Analysis of 1000 autopsied cases. Cancer 1950; 3: 74–85.

    Article  PubMed  CAS  Google Scholar 

  36. Yap HY, Tashima CK, Blumenschein GR, Eckles N. Diabetes insipidus and breast cancer. Arch Intern Med 1979; 139: 1009 1011.

    Google Scholar 

  37. Boogerd W, Hart AAM, van der Sande JJ, Engelsman E. Meningeal carcinomatosis in breast cancer: prognostic factors and influence of treatment. Cancer 1991; 67: 1685–1695.

    Article  PubMed  CAS  Google Scholar 

  38. Jayson C, Howell A, Harris M, Morgenstern G, Chang J, Ryder WD. Carcinomatous meningitis in patients with breast cancer. Cancer 1994; 74: 3135–3141.

    Article  PubMed  CAS  Google Scholar 

  39. Clamon G, Doebbeling B. Meningeal carcinomatosis from breast cancer: spinal cord vs. brain involvement. Breast Cancer Res Treatm 1987; 9: 213–217.

    Article  CAS  Google Scholar 

  40. Kokkoris CHP. Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid ? Cancer 1983; 51: 154–160.

    Article  PubMed  CAS  Google Scholar 

  41. Murray JJ, Greco FA, Wolff SN, Hainsworth JD. Neoplastic meningitis, marked variations of cerebrospinal fluid composition in the absence of extradural block. Am J Med 1983; 75: 289–294.

    Article  PubMed  CAS  Google Scholar 

  42. Boogerd W, Vroom ThM, van Heerde P, Brutel de la Riviére G, Peterse JL, et al. CSF cytology versus immunocytochemistry in meningeal carcinomatosis. J Neurol Neurosurg Psychiatry 1988; 51: 142–145.

    Article  PubMed  CAS  Google Scholar 

  43. Cibas ES, Malkin MG, Posner JB, Melamed MR. Detection of DNA abnormalities by flow cytometry in cells from cerebrospinal fluid. Am J Clin Pathol 1987; 88: 570–577.

    PubMed  CAS  Google Scholar 

  44. Van Oostenbrugge RJ, Hopman AHN, Arends JW, Ramaekers FCS, Twijnstra A. Treatment of leptomeningeal metastases evaluated by interphase cytogenetics. J Clin Oncol 2000; 18: 2053–2058.

    PubMed  Google Scholar 

  45. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal carcinomatosis from solid tumors: experience with 90 patients. Cancer 1982; 49: 759–772.

    Article  PubMed  CAS  Google Scholar 

  46. Bach F, Bjerregaards B, Sölétormos G, Bach FW, Horn T. Diagnostic value of cerebrospinal fluid cytology in comparison with tumor marker activity in central nervous system metastases secondary to breast cancer. Cancer 1993; 72: 2376–2382.

    Article  PubMed  CAS  Google Scholar 

  47. Stockhammer G, Poewe W, Burgstaller S, Deisenhammer F, Muigg A, Kiechl S, et al. Vascular endothelial growth factor in CSF. Neurology 2000; 54: 1670–1675.

    Article  PubMed  CAS  Google Scholar 

  48. Pannullo SC, Reich JB, Krol G, Deck MDF, Posner JB. MRI changes in intragranial hypotension. Neurology 1993; 43: 919–926.

    Article  PubMed  CAS  Google Scholar 

  49. Shapiro WR, Young DF, Metha BM. Methotrexate: distribution in the cerebrospinal fluid after intravenous, intraventricular and lumbar injections. N Engl J Med 1975; 293: 161–166.

    Article  PubMed  CAS  Google Scholar 

  50. Lishner M, Perrin RG, Feld R, Messner HA, Tuffnell PG, Elhakim T, et al. Complications associated with Ommaya reservoirs in patients with cancer: the Princess Margaret Hospital experience and a review of the literature. Arch Intern Med 1990; 150: 173–176.

    Article  PubMed  CAS  Google Scholar 

  51. Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994; 44: 1463–1469.

    Article  PubMed  CAS  Google Scholar 

  52. Hitchins RN, Bell DR, Woods RL, Levi JA. A prospective trial of single agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987; 5: 1655–1662.

    PubMed  CAS  Google Scholar 

  53. Blaney SM, Balis FM, Poplack DG. Pharmacologic approaches to the treatment of meningeal malignancy. Oncology 1991; 5: 107–116.

    PubMed  CAS  Google Scholar 

  54. Shapiro WR, Posner JB, Ushio Y, Chernik NL, Young DF. Treatment of meningeal neoplasms. CancerTreatmRep 1977; 61: 733–743.

    CAS  Google Scholar 

  55. Ongerboer de Visser BW, Somers R, Nooyen WH, van Heerde P, Hart AAM, McVie JG. Intraventricular methotrexate therapy of leptomeningeal metastases from breast carcinoma. Neurology 1983; 33: 1565–1572.

    Article  PubMed  CAS  Google Scholar 

  56. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 1993; 11: 561–569.

    PubMed  CAS  Google Scholar 

  57. Grant R, Naylor B, Greenberg HS, Junck L. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol 1994; 51: 457–461.

    Article  PubMed  CAS  Google Scholar 

  58. Bleyer WA, Poplack DG, Simon RM, Henderson ES, Leventhal BG, Zeigler JL, et al. `Concentration Y time’ methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 1978; 51: 835–842.

    PubMed  CAS  Google Scholar 

  59. Glantz MJ, Hall WA, Cole BF, Chozick BS, Shannon CN, Wahlberg L, et al. Diagnosis, managment and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995; 75: 2919–2931.

    Article  PubMed  CAS  Google Scholar 

  60. Chamberlain MC, Kormanik PA. Prognostic significance of 111lndium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 1996; 46: 1674–1677.

    Article  PubMed  CAS  Google Scholar 

  61. Mason WP, DeAngelis LM, Yeh SDJ. 111Indium-DTPA cerebrospinal fluid (CSF) studies in leptomeningeal metastases (LM) predict intrathecal methotrexate (MTX) distribution and response to therapy. Proc ASCO 1996; 15: 155.

    Google Scholar 

  62. Bleyer WA. Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treatm Rep 1981; 65: 89–98.

    Google Scholar 

  63. Boogerd W, van der Sande JJ, Moffie D. Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry 1988; 51: 1277–1283.

    Article  PubMed  CAS  Google Scholar 

  64. Watterson J, Toogood I, Nieder M, Morse M, Frierdisch S, Lee Y, et al. Excessive spinal cord toxicity from intensive central nervous system-directed therapies. Cancer 1994; 74: 3034–3041.

    Article  PubMed  CAS  Google Scholar 

  65. Nakagawa H, Yamada M, Maeda N, Iwatsuki K, Hirayama A, Ikenaka K Clinical trial of intrathecal administration of 5-fluoro2’-deoxyuridine for treatment of meningeal dissemination of malignant tumors. J Neuro-Oncol 1999; 45: 175–183.

    Article  CAS  Google Scholar 

  66. Benjamin JC, Moss T, Moseley RP, Maxwell R, Coakham HB. Cerebral distribution of immunoconjugate after treatment for neo-plastic meningitis using an intrathecal radiolabeled monoclonal antibody. Neurosurg 1989; 25: 253–258.

    Article  CAS  Google Scholar 

  67. Moseley RP, Benjamin JC, Ashpole RD, Sullivan NM, Bullimore JA, Coakham HB, et al. Carcinomatous meningitis: antibody-guided therapy with I-131 HMFG1. J Neurol Neurosurg 1991; 54: 260–265.

    Article  CAS  Google Scholar 

  68. Siegal T, Sandbank U, Gabrizon A, Siegal T, Mizrachi R, David EB, et al. Alteration of blood-brain-CSF barrier in experimental meningeal carcinomatosis: a morphologic and adriamycinpenetration study. J Neuro-Oncol 1987; 4: 233–242.

    Article  CAS  Google Scholar 

  69. Ushio Y, Shunizuk K, Aragaki Y, Arita N, Hayakawa T, Mogami H. Alteration of blood-CSF barrier by tumor invasion into the meninges. J Neurosurg 1981; 55: 445–449.

    Article  PubMed  CAS  Google Scholar 

  70. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors. Cancer 1998; 82: 1756–1763.

    Article  PubMed  CAS  Google Scholar 

  71. Boogerd W, Dorresteijn LDA, van der Sande JJ, de Gast GC, Bruning PF. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 2000; 55: 117–119.

    Article  PubMed  CAS  Google Scholar 

  72. Boogerd W, van der Sande JJ, Kröger R. Early diagnosis and treatment of spinal epidural metastasis in breast cancer: a prospective study. J Neurol Neurosurg Psychiatry 1992; 55: 1188–1193.

    Article  PubMed  CAS  Google Scholar 

  73. Schiff D, O’Neill BP, Wang C-H, O’Fallon JR. Neuroimaging and treatment implications of patients with multiple epidural spinal metastases. Cancer 1998; 83: 1593–1601.

    Article  PubMed  CAS  Google Scholar 

  74. Boogerd W, van der Sande JJ. Diagnosis and treatment of spinal cord compression in malignant disease. Cancer Treatm Rev 1993; 19: 129–150.

    Article  CAS  Google Scholar 

  75. Helweg-Larsen S, Hansen SW, Sorensen PS. Second occurrence of symptomatic metastatic spinal cord compression and findings of multiple spinal epidural metastases. Int J Radiat Oncol Biol Phys 1995; 33: 595–598.

    Article  PubMed  CAS  Google Scholar 

  76. Graus F, Krol G, Foley K. Early diagnosis of spinal epidural metastasis: correlation with clinical and radiological findings. Proc ASCO 1985; 4: 269.

    Google Scholar 

  77. Boogerd W, Kröger R. Intravenous contrast in spinal computed tomography to identify epidural metastases. Clin Neurol Neurosurg 1991; 93: 195–199.

    Article  PubMed  CAS  Google Scholar 

  78. Maranzano E, Latini P. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys 1995; 32: 959–967.

    Article  PubMed  CAS  Google Scholar 

  79. Greenberg HS, Kim JH, Posner JB. Epidral spinal cord compression from metastatic tumour: results with a new treatment protocol. Ann Neurol 1980; 8: 361–366.

    Article  PubMed  CAS  Google Scholar 

  80. Sorensen PS, Helweg-Larsen S, Mouridsen H, Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer 1994; 30: 22–27.

    Article  Google Scholar 

  81. Delattre JY, Arbit E, Thaler HT, Rosenblum MK, Posner JB. A dose-response study of dexamethasone in a model of spinal cord compression caused by epidral tumor. J Neurosurg 1989; 70: 920–925.

    Article  PubMed  CAS  Google Scholar 

  82. Kaminsky HJ, Diwan VG, Ruff RL. Second occurrence of spinal epidural metastases. Neurology 1991; 41: 744–746.

    Article  Google Scholar 

  83. Van der Sande JJ, Boogerd W, Kröger R, Kappelle AC. Recurrent spinal epidural metastases: a prospective study with a complete follow up. J Neurol Neurosurg Psychiatry 1996; 66: 623–627.

    Article  Google Scholar 

  84. Schiff D, Shaw EG, Casino TL. Outcome after spinal reirradiation for malignant epidural spinal cord compression. Ann Neurol 1995; 37: 583–589.

    Article  PubMed  CAS  Google Scholar 

  85. Siegal T, Siegal T. Surgical decompression of anterior and posterior malignant epidural tumors compressing the spinal cord: a prospective study. Neurosurg 1985; 17: 424–432.

    Article  CAS  Google Scholar 

  86. Fidler MW. Anterior decompression and stabilization of metastatic spinal fractures. J Bone Joint Surg 1986; 68: 83–90.

    CAS  Google Scholar 

  87. Sundaresan N, Digiacinto GV, Hughes JEO, Cafferty M, Valegio T. Treatment of neoplastic spinal cord compression: Results of a prospective study. Neurosurg 1991; 29: 645–650.

    CAS  Google Scholar 

  88. Boogerd W, van der Sande JJ, Kröger R, Bruning PF, Somers R. Effective systemic therapy for spinal epidural metastasis from breast carcinoma. Eur J Cancer Clin Oncol 1989; 25: 149–153.

    Article  PubMed  CAS  Google Scholar 

  89. Jansen BP, Pillay M, de Bruin HG, van den Bent MJ, Vecht CJ, Sillevis Smitt PA. 99mTc-SPECT in the diagnosis of skull base metastasis. Neurology 1997; 48: 1326–1330.

    Article  PubMed  CAS  Google Scholar 

  90. Hall SM, Buzdar U, Blumenschein R. Cranial nerve palsies in metastatic breast cancer due to osseous metastasis without intracranial involvement. Cancer 1983; 52: 180–184.

    Article  PubMed  CAS  Google Scholar 

  91. Bruyn RPM, Boogerd W. The numb chin. Clin Neurol Neurosurg 1991; 93: 187–193.

    Article  CAS  Google Scholar 

  92. McCormick BA, Abramson DH. Ocular metastases. In: Diseases of the Breast. Harris JR, ed. Lippincott, 2000, pp. 889–891.

    Google Scholar 

  93. Dao TH, Rahmouni A, Campana F, Laurent M, Asselain B, Fourquet A. Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imaging. Radiology 1993; 1187: 751.

    Google Scholar 

  94. Thyagarajan D, Cascino T, Harms G. Magnetic resonance imaging in brachial plexopathy of cancer. Neurology 1995; 45: 421–427.

    Article  PubMed  CAS  Google Scholar 

  95. Lederman RJ, Wilbourn AJ. Brachial plexopathy: recurrent cancer or radiation? Neurology 1984; 34: 1331–1335.

    Article  PubMed  CAS  Google Scholar 

  96. Harper CM, Thomas JE, Cascino TL, Litchy WJ. Distinction between neoplastic and radiation-induced brachial plexopathy, with emphasis on the role of EMG. Neurology 1989; 39: 502–506.

    Article  PubMed  Google Scholar 

  97. Gerard JM, Franck N, Moussa Z, Hildebrand J. Acute ischemic brachial plexus neuropathy following radiation therapy. Neurology 1989; 39: 450–451.

    Article  PubMed  CAS  Google Scholar 

  98. Dalmau JO, Posner JB. Paraneoplastic syndromes. Arch Neurol 1999; 56: 405–408.

    Article  PubMed  CAS  Google Scholar 

  99. Greenlee JE. Cytotoxic T cells in paraneoplastic cerebellar degeneration. Ann Neurol 2000; 47: 4–5.

    Article  PubMed  CAS  Google Scholar 

  100. Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000; 47: 9–17.

    Article  PubMed  CAS  Google Scholar 

  101. Escudero D, Barnadas A, Codina M, Fueyo J, Graus F. AntiRi-associated paraneoplastic neurologic disorder without opsoclonus in a patient with breast cancer. Neurology 1993; 43: 1605–1606.

    Article  PubMed  CAS  Google Scholar 

  102. Dropcho EJ, Kline LB, Riser J. Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus-myoclonus. Neurology 1993; 43: 207–211.

    Article  PubMed  CAS  Google Scholar 

  103. Rogers LR. Cerebrovascular complications in cancer patients. Oncology 1994; 8: 23–30.

    PubMed  CAS  Google Scholar 

  104. Wall JG, Weiss RB, Norton L, Perloff M, Rice MA, Korzun AH, et al. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B study. Am J Med 1989; 87: 501–504.

    Article  PubMed  CAS  Google Scholar 

  105. Rogers JS, Murgo AJ, Fontana JA, Raich PC. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 1988; 6: 276–281.

    PubMed  Google Scholar 

  106. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9: 286–294.

    PubMed  CAS  Google Scholar 

  107. Clouston PD, DeAngelis LM, Posner JB. The spectrum of neurological disease in patients with systemic cancer. Ann Neurol 1992; 31: 268–273.

    Article  PubMed  CAS  Google Scholar 

  108. Van Dam FSAM, Schagen SB, Muller MJ, Boogerd W, van der Wall E, Droogleever Fortuyn ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90: 210–218.

    Article  PubMed  Google Scholar 

  109. Schagen SB, van Dam FSAM, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85: 640–650.

    Article  PubMed  CAS  Google Scholar 

  110. Boogerd W. Neurological complications of chemotherapy. In: Handbook of Clinical Neurology. Vinken PJ, Bruyn GW, eds. Elsevier Science, 1995, pp. 527–546.

    Google Scholar 

  111. Boogerd W, Moffie D, Smets LA. Early blindness and coma during intrathecal chemotherapy for meningeal carcinomatosis. Cancer 1990; 65: 452–457.

    Article  PubMed  CAS  Google Scholar 

  112. Fishman ML, Bean SC, Gogan DG. Optic atrophy following prophylactic chemotherapy and cranial radiation for acute lymphocytic leukemia. Am J Ophthalmol 1976; 82: 571–576.

    PubMed  CAS  Google Scholar 

  113. Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer 1992; 69: 2961–2964.

    Article  PubMed  CAS  Google Scholar 

  114. Postma TJ, Vermorken JB, Liefting AJM, Pinedo HM, Heimans JJ. Paclitaxel-induced neuropathy. Ann Oncol 1995; 6: 489–494.

    PubMed  CAS  Google Scholar 

  115. Capri G, Munzone E, Tarenzi E, Fulfaro F, Gianni L, Caraceni A, et al. Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J Natl Cancer Inst 1994; 86: 1099–1101.

    Article  PubMed  CAS  Google Scholar 

  116. Hilkens PHE, Verweij J, Stoter G, Vecht CHJ, van Putten WLJ, van den Bent MJ. Peripheral neurotoxicity induced by docetaxel. Neurology 1996; 46: 104–108.

    Article  PubMed  CAS  Google Scholar 

  117. Freilich RJ, Balmaceda C, Seidman AD, Rubin M, De Angelis LM. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996; 47: 115–118.

    Article  PubMed  CAS  Google Scholar 

  118. Van Daal WAJ, van der Kogel AJ. Side effects of radiation on the nervous system. In: Neuro-Oncology. Twijnstra A, Keyser A, Ongerboer de Visser BW, eds. Elsevier Science, 1993, pp. 357–365.

    Google Scholar 

  119. Salner AL, Botnick LE, Herzog AG, Goldstein MA, Harris JR, Levene MB, et al. Reversible brachial plexopathy following primary radiation therapy for breast cancer. Cancer Treat Rep 1981; 65: 797–802.

    PubMed  CAS  Google Scholar 

  120. Pierce SM, Recht A, Lingos TI, Abner A, Vicini F, Silver B, et al. Long-term radiation complications following conservative surgery and radiation therapy in patients with early stage breast cancer. Int J Radiation Oncology Biol Phys 1992; 23: 915–923.

    Article  CAS  Google Scholar 

  121. Stoll BA, Andrews JT. Radiation-induced peripheral neuropathy. BMJ 1966; 1: 834–837.

    Article  PubMed  CAS  Google Scholar 

  122. Powell S, Cooke J, Parsons C. Radiation-induced brachial plexus injury: follow-up of two different fractionation schedules. Radiother Oncol 1990; 18: 213–220.

    Article  PubMed  CAS  Google Scholar 

  123. Olsen NK, Pfeiffer P, Johannsen L, Schf der H, Rose C. Radiation-induced brachial plexopathy: neurological follow-up in 161 recurrence-free breast cancer patients. Int J Radiat Oncol Biol Phys 1993; 26: 43–49.

    Article  PubMed  CAS  Google Scholar 

  124. Vecht CHJ, van de Brand HJ, Wajer OJM. Post-axillary dissection pain in breast cancer due to a lesion of the intercostobrachial nerve. Pain 1989; 38: 171–176.

    Article  PubMed  CAS  Google Scholar 

  125. Fulton DS, Levin VA, Gutin P, Edwards MSB, SeagerML, Stewart J, et al. Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant breast tumors and systemic tumors. Cancer Chemother Pharmacol 1982; 8: 285–291.

    Article  PubMed  CAS  Google Scholar 

  126. Helweg-Larsen S, Rasmussen B, S“rensen PS. Recovery of gait after radiotherapy in paralytic patients with metastatic epidural spinal cord compression. Neurology 1990; 40: 1234–1236.

    Article  PubMed  CAS  Google Scholar 

  127. DeAngelis LM, Delattre J-Y, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989; 39: 789–796.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Willem Boogerd MD,PHD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Neurology, University of Virginia Medical Center, Charlottesville, VA, USA

    David Schiff MD

  2. Center for Neuro-Oncology Dana-Farber Cancer Institute; and Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA

    Patrick Y. Wen MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Boogerd, W. (2003). Neuro-Oncologic Complications of Breast Cancer. In: Schiff, D., Wen, P.Y. (eds) Cancer Neurology in Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-317-0_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-317-0_21

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-4703-4

  • Online ISBN: 978-1-59259-317-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation